Employers Hold the Line on GLP-1 Weight Loss Drug Coverage
Employer coverage of GLP-1 drugs for obesity has stalled at 36%, with many companies seeking workarounds rather than expanding benefits.
The employer health benefits landscape is showing a notable resistance to the GLP-1 drug boom. Despite surging public demand for medications like Ozempic and Wegovy, a new survey finds that roughly 36% of employers currently cover GLP-1 drugs for both diabetes and weight loss — a figure unchanged from 2025 and only marginally higher than the 34% recorded in 2024. That near-flat trajectory suggests corporate benefit managers are pumping the brakes even as these drugs dominate headlines and physician waiting rooms alike.
The stagnation is meaningful because GLP-1 medications have demonstrated genuine clinical value beyond glucose control, with mounting evidence supporting their role in reducing cardiovascular risk and managing chronic obesity. Yet the cost burden remains a decisive factor for employers weighing expanded coverage. Rather than broadening access outright, many companies appear to be threading the needle — maintaining narrow eligibility criteria, imposing prior authorization requirements, or steering employees toward managed utilization programs that limit exposure to the drugs' steep list prices.
Read more IRS Eases Penalty Rules for Taxpayers Who Made Filing Errors →
This dynamic creates a widening gap between what medicine considers best practice and what workplace insurance actually delivers. Employees without diabetes diagnoses — the group most likely to seek GLP-1s purely for weight management — remain the least protected under current employer plan designs. The practical effect is that access continues to correlate heavily with diagnosis category rather than clinical need, a distinction that physicians and patient advocates have increasingly questioned.
From a policy and market perspective, the employer hesitation may also reflect uncertainty about long-term drug pricing negotiations and whether proposed Medicare reforms will eventually ripple into the commercial insurance market. Until employers see a clearer cost trajectory, the survey data suggests most are content to hold their current position rather than absorb an open-ended financial commitment. The result is a benefits landscape where coverage exists on paper for millions of workers but meaningful access remains far more restricted in practice.
Continue reading at US Top News and Analysis.
